Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1

Conditions

Head and Neck Neoplasms 2Carcinoma, Squamous Cell 2Squamous Cell Carcinoma of Head and Neck 1Esophageal Squamous Cell Carcinoma 1Anus Neoplasms 1

Interventions

Cyclophosphamide 8fludarabine 7pembrolizumab 6aldesleukin 4Interleukin-2 3spartalizumab 2fludarabine phosphate 2entinostat 2Vorinostat 2Trastuzumab 2Nivolumab 2Erlotinib Hydrochloride 2Biopsy 2Adoptive Transfer 2trastuzumab deruxtecan 1tislelizumab 1tipifarnib 1prexasertib 1oncogene protein E7, Human papillomavirus type 16 1nanocis 1enzalutamide 1cemiplimab 1bintrafusp alfa protein, human 1atezolizumab 1abiraterone 1Tomography, X-Ray Computed 1Thalidomide 1Technetium-99 1Taxes 1SRA737 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anus Neoplasms × ON 01910 × Head & Neck × Clear all
NCT01807546 2017-06-26

Oral Rigosertib for Squamous Cell Carcinoma

Traws Pharma, Inc.

Phase 2 Completed
64 enrolled
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Anus Neoplasms, Carcinoma, Squamous Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡